ECM
TXG icon

Endurant Capital Management’s 10x Genomics TXG Stock Holding History

Endurant Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-71,044
Closed -$2.93M – 51
2023
Q3 		$2.93M Buy
+71,044
New +$3.7M 2.63% 12
2023
Q1 		– Sell
-30,357
Closed -$1.11M – 66
2022
Q4 		$1.11M Buy
+30,357
New +$993K 0.45% 36
2022
Q2 		– Sell
-24,923
Closed -$1.9M – 75
2022
Q1 		$1.9M Buy
+24,923
New +$2.18M 0.5% 39

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Endurant Capital Management's TXG Position: Q4 2023 in Review

Endurant Capital Management sold out of 10x Genomics (TXG) in Q4 2023, closing a stake of 71,044 shares — an estimated $2.93M sold.

Endurant Capital Management first reported a position in TXG in Q1 2022 and held it in 3 quarters. The position peaked at $2.93M in Q3 2023. 275 funds tracked by Wall St. Rank hold TXG as of Q4 2023.

  • Endurant Capital Management reported no remaining 10x Genomics position as of Q4 2023 after selling out during the quarter.
  • Endurant Capital Management sold 71,044 10x Genomics shares in Q4 2023, an estimated $2.93M.
  • Endurant Capital Management first reported a position in 10x Genomics in Q1 2022 and held it in 3 quarters.
  • Endurant Capital Management's 10x Genomics position peaked at $2.93M in Q3 2023.
  • 275 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2023.

Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.